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Abstract 
Background: Concurrent thyroid cancer (TC) and hyperthyroidism (HT) is rare though increasingly being reported. 
HT due to TC is much rarer and more challenging especially in Africa where TC and HT have significant case fatality 
rates.
Case presentation: We present a 37-year-old Cameroonian female who had been on irregular regimens of pro-
pranolol and digoxin as treatment for worsening palpitations for 12 months. She came to our district hospital for 
her propranolol medication refill. We fortuitously identified features of HT and found a left uninodular goiter with no 
cervical lymphadenopathy. She was referred for thyroid assessment which suggested primary HT and an enlarged 
heterogeneous left lobe with a well-defined homogenous solid mass. We restarted her on propranolol and referred 
her for a course of methimazole. At the referral hospital, she also underwent a left thyroid lobectomy. The resected 
lobe was sent for histopathology which revealed a neoplastic nodule with features suggestive of a papillary thyroid 
cancer (PTC) causing HT. The patient’s clinical progress postoperatively was good and there was regression of hyper-
thyroid symptoms.
Conclusions: The historical, clinical, and laboratory findings were suggestive of HT due to PTC. A high index of suspi-
cion, prompt referral and counter-referral lead to a positive outcome of such a rare case in a resource poor setting. We 
advocate for systematic and careful evaluation of all thyroid nodules.
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Background
Thyroid cancer (TC) is the most common malignant 
endocrine tumour worldwide [1–3] but accounts for 
only 1 % of global malignancies [4]. It is, thus, a relatively 
uncommon cancer [4]. Papillary thyroid cancer (PTC) is 
the predominant variant of TC [1, 3, 5, 6].
Hyperthyroidism (HT) is a state of excessive thyroid 
hormone production [1]. Its most common aetiologies 
are Graves’ disease, toxic uninodular goiter (usually a 
toxic adenoma) and toxic multinodular goiter (Plummer’s 
disease) [1].
The co-existence of TC and HT is rare, although there 
are increasing reports [7–11]. The association of TC and 
HT poses serious diagnostic, therapeutic and prognostic 
enigmas [8, 9, 12, 13]. More so, it is much rarer and more 
challenging for HT to be due to TC which is instead usu-
ally associated with euthyroidism [7–9, 13, 14].
In Africa, thyroid diseases carry significant morbid-
ity and mortality with the leading causes being TC and 
HT [2]. This is accounted for by the late presentation of 
patients, lack of robust diagnostic facilities, and poor 
accessibility to healthcare resources [2].
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We report here an additional and nearly missed case of 
concurrent PTC and HT from a remote district of Cam-
eroon. We attributed the HT to the PTC.
Case presentation
A 37-year-old woman purposely came to the outpa-
tient department of our district hospital in the North 
West Region of Cameroon for a refill of her proprano-
lol medication. She reported taking the drug routinely 
for palpitations. On further inquiry, she reported being 
well until 12 months prior to presentation when she sud-
denly became aware of her heartbeat, initially on moder-
ate exertion and then even at rest. It had been recurrent 
and lasting several minutes each time it occurred. It pro-
gressively became associated with dyspnoea initially on 
moderate exertion and then on mild exertion, such that 
she had to quit farming which was her main source of 
income. After consulting at various health facilities in 
the North West Region of Cameroon, she was prescribed 
irregular and alternate daily regimens of 40  mg pro-
pranolol and 0.25 mg digoxin which she had been taking 
for 12 months at the time she presented at our hospital. 
Although the medications conferred her some relieve, 
she noticed a progressive weight loss over the 12-months 
period prior to consulting at our hospital, from 85 to 
58  kg despite an abnormal increase in her appetite for 
food. She also experienced frequent watery stools (aver-
agely six times daily). About 6  months prior to presen-
tation, she complained of heat intolerance and profuse 
sweating resulting in sleeping with minimal clothing. In 
addition, she noticed spontaneous resting tremors of her 
hands which started at the same time as the heat intoler-
ance. Three months prior to presentation at our hospital, 
she noticed a painless lump on her neck that progres-
sively increased in size.
On reviewing her medical records, we noticed a num-
ber of investigations requested at various hospitals which 
she visited during the 8 months preceding her presenta-
tion at our hospital. These included electrocardiographs, 
echocardiograms, HIV tests, full blood counts, fast-
ing blood sugar, thyroid hormone assays, which were 
all without particularity but for the electrocardiography 
results which always showed a sinus tachycardia. She has 
no known history of exposure to radiations or family his-
tory of malignancies.
Physical examination revealed a chronically ill-looking 
middle aged woman. Her eyes were normal (Fig. 1). Her 
voice was clear. She had fine resting tremors of her hands 
with her arms outstretched. There was a left anterolateral 
neck mass measuring 4  ×  3  cm (Fig.  2). The mass was 
rubbery, mobile, non-tender, moved with swallowing, 
and not fixed to overlying or underlying tissue. No bruit 
was heard over the mass. There was no palpable cervical 
lymphadenopathy. Her vital signs were normal but for 
regular respiratory and pulse rates of 35  breaths/min 
and 104  beats/min respectively. Her BMI was 20.1  kg/
m2. There was discrete bilateral pedal pitting oedema. 
The rest of the physical examination was without notable 
findings. In view of this presentation, a presumptive diag-
nosis of HT was made and we placed her on proprano-
lol, 40  mg twice daily. Our hospital was not equipped 
with the necessary diagnostic tools, so we referred the 
patient to a regional hospital which is about 10 km from 
our locality. To confirm our diagnosis, we requested for a 
functional [serum T3, T4, Thyroid stimulating hormone 
(TSH)] and structural (ultrasound) assessment of the thy-
roid. The patient was counter-referred to us with the fol-
lowing results:  
1. Functional assessment of the thyroid: levels of serum 
T3, T4, and TSH (Table 1).
2. Structural assessment of the thyroid (ultrasound 
scan): The left thyroid lobe appeared enlarged, het-
Fig. 1 Eyes of the patient
Fig. 2 Anterolateral neck mass
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erogeneous, with a fairly iso-echoic, well-defined 
homogenous solid mass (3.6 × 1.8 × 2.9 cm in size). 
The right lobe was without particularity. No cervical 
lymphadenopathy was observed.
In view of these findings, we concluded on a primary 
HT most likely due to a toxic uninodular goiter. Again, 
due to the limited resources in our hospital, we referred 
the patient to a hospital which is over 30  km from our 
locality for initiation of a course of methimazole. She was 
placed on 60 mg methimazole daily, 4 weeks after which 
she underwent a left thyroid lobectomy. The resected 
lobe (Fig. 3) was sent for histopathology. The postopera-
tive course was uneventful.
The lobe weighed 33.5  g and was received in for-
malin as two grey-tan soft tissue fragments: a large 
(6.5 ×  5 ×  3.5  cm) and a small (3 ×  1.5 ×  1  cm) frag-
ment. Cutting demonstrated a red tan cut surface with 
a 3 × 2.3 × 2 cm nodule inside the bigger piece. Micro-
scopic examination of representative sections of the large 
fragment with a full thickness section of the nodular 
structure revealed a nodular proliferation of enlarged 
pale cells with marginated chromatin and overlapping 
nuclei. Pink “bubble gum”-like colloid was focally noted. 
The lesion was partially encapsulated and displayed 
areas with fibrosis and more follicular appearance of the 
aggregates. Based on these, a histological diagnosis of 
PTC (pT2N0M0) was made.
We monitored the patient through scheduled regular 
visits and referrals. Figure  4 shows the Incision site on 
the anterior aspect of the neck 2 weeks after lobectomy. 
We observed a progressive decline in hyperthyroid symp-
toms and signs: the palpitations regressed as well as the 
diarrhoea and polyphagia; the heat intolerance regressed 
and 1 month postoperatively, her weight increased from 
58 to 68 kg.
Discussion
We report a fortuitous finding of concurrent HT and 
PTC from a resource-limited setting. The case is more 
perplexing as the HT seemed to stem from the PTC. It is 
a challenge to manage such a rare case from a remote dis-
trict of Cameroon as the country has a poorly developed 
healthcare referral system and only 20 % of the popula-
tion has access to referral centres [15].
Graves’ disease, though the most common cause of 
HT [1, 2, 16], is less likely the diagnosis since the goiter 
was not diffuse, the eyes were normal and there was no 
pretibial myxoedema. A hyperfunctioning thyroid nod-
ule therefore took precedence as the probable aetiologi-
cal diagnosis, with a toxic adenoma being the most likely 
aetiology. Since the patient’s TSH levels were low, the 
most appropriate next step would have been a thyroid 
scan (scintigraphy) to determine if the nodule is hot [1, 
7, 17]. That notwithstanding, even if the HT were due to 
a hyperfunctioning (hot) nodule, it is very rare for such 
Table 1 Functional assessment of  thyroid gland of  the 
patient
Test Results Normal range Comment
T3 >5.0 (0.8–2.0) ng/mL Elevated
T4 23.3 (5.0–13.0) ɱg/dL Elevated
TSH 0.13 (0.4–7.0) ɱIU/mL Low
Fig. 3 Resected thyroid lobe (2 fragments)
Fig. 4 Incision site 2 weeks after lobectomy
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a nodule to have malignant potentials, thus, they are sel-
dom biopsied after scintigraphy [7, 8, 17]. Being deficient 
in thyroid scan in our hospital facilities, the next means 
to confirm the characteristics of the thyroid nodule was 
by histopathological analysis. However, a limitation in the 
management of this case is that though histopathology 
can be done on a resected lobe, histopathology through 
fine needle aspiration cytology would have allowed for 
proper planning of the surgical approach to be used [7, 
11, 17]. This is because it is suggested that toxic thyroid 
cancers are best treated by total thyroidectomy while 
incidental carcinomas can be managed by subtotal thy-
roidectomy or lobectomy [9].
Interestingly, histopathology revealed a PTC. Given 
the partial encapsulation of the neoplastic nodule in this 
case, the lesion could be further classified as an encap-
sulated variant of PTC. The differential diagnosis also 
included follicular adenoma with papillary hyperplasia 
but the extensive nuclear changes observed were typical 
of PTC (pT2N0M0). This case is again unusual in that 
most malignant thyroid tumours associated with HT that 
have been reported so far are papillary thyroid microcar-
cinomas (nodule <1  cm or pT1) [7]. Nonetheless, Mir-
fakhraee et  al. in 2013 reported that amongst patients 
with hyperfunctioning TC, a greater rate of frank bio-
chemical HT was observed in patients with larger nod-
ules as in our case [8]. The many follicular cells observed 
in the neoplastic lesion were suggestive of follicular 
hyperactivity which is seen in toxic TC [7].
If HT is due to a tumour cell mass, demonstrated in 
most cases by clinical-histopathological correlation, 
a toxic TC is diagnosed [9]. An ambiguity, however, 
remains because a scintigraphically hot nodule was not 
confirmed. Concomitant TC and HT can either be in the 
form of a fortuitous malignancy in the thyroid gland of 
a clinically hyperthyroid patient or as a TC presenting 
with HT with the latter being rarer [9, 14, 17]. The two 
can be distinguished via histopathology, with the lack of 
hyperplastic thyroid tissue suggesting a hyperfunctioning 
TC [9] as in the case presented. Again, with retrospect to 
the lack of ultrasound findings of increase vascularity and 
diffuse enlargement of thyroid tissue, further credence is 
lent to the autonomous nature of the tumour cell mass 
[9]. In terms of risk factors, based on the study by Mir-
fakhraee et al., patients with malignant hot nodules seem 
more likely to be younger and females [8] as is the case 
with the patient presented.
Hyperthyroidism due to TC is explained by somatic 
mutations in TSH receptor genes of the cancer cells. 
These mutations lead to constitutive activation of intra-
cellular cyclic Adenosine Monophosphate (cAMP) cas-
cade which induces hormonogenesis and thus HT [7, 9].
Conclusions
The historical, clinical, and laboratory findings of the case 
we report concurred with HT due to PTC. A high index 
of suspicion should be the attitude towards every thyroid 
nodule. Despite the difficult diagnostic and therapeutic 
terrain in our resource-limited setting, a good referral 
and counter-referral system lead to a positive outcome. 
We advocate for systematic and careful evaluation of all 
thyroid nodules.
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